Jaguar Health Inc. (NASDAQ:JAGX) finished Friday with a subtraction of -$0.02 to close at $0.40, a downside of -4.08 percent. An average of 809,460 shares of common stock have been traded in the last five days. There was a fall of -$0.1000 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 609,020 shares traded, while the 50-day average volume stands at 748,428.
JAGX stock has decreased by -33.97% in the last month. The company shares reached their 1-month lowest point of $0.3921 on 08/25/23. With the stock rallying to its 52-week high on 01/11/23, shares of the company touched a low of $0.40 and a high of $19.35 in 52 weeks. It has reached a new high 4 times so far this year and lost -93.86% or -$6.1175 in price. In spite of this, the price is down -97.93% from the 52-week high.
Valuation Metrics
Jaguar Health Inc. (JAGX) stock’s beta is 1.89. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.18, the price-to-book (PB) ratio at 0.28.
Financial Health
The quick ratio of Jaguar Health Inc. for the three months ended June 29 was 0.80, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 2.36 and a total debt to equity ratio of 4.47 for the quarter ending June 29. Jaguar Health Inc.’s EBITDA margin for the year ending June 29 is -268.68%. Its gross profit as reported stood at $9.94 million compared to revenue of $11.96 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Jaguar Health Inc.’s return on assets was -81.10%.
Earnings Surprise
For the three-month period that ended June 29, Jaguar Health Inc. had $16.85 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$12.15 million in the quarter, while revenues of -$12.2 million were grew 22.88%. The analyst consensus anticipated Jaguar Health Inc.’s latest quarter earnings to come in at -$1.53 per share, but it turned out to be -$0.69, a 54.90% surprise. For the quarter, EBITDA amounted to -$4.35 million. Shareholders own equity worth $19.12 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Jaguar Health Inc. (JAGX) price momentum. RSI 9-day as of the close on 25 August was 18.18%, suggesting the stock is oversold, with historical volatility in this time frame at 74.25%.
As of today, JAGX’s price is $0.4369 -20.00% or -$0.1000 from its 5-day moving average. JAGX is currently trading -34.68% lower than its 20-day SMA and -31.62% lower than its 100-day SMA. However, the stock’s current price level is -42.85% below the SMA50 and -96.00% below the SMA200.
The stochastic %K and %D were 4.03% and 4.46%, respectively, and the average true range (ATR) was 0.0423. With the 14-day stochastic at 3.47% and the average true range at 0.0448, the RSI (14) stands at 27.38%. The stock has reached -0.0462 on the 9-day MACD Oscillator while the 14-day reading was at -0.0822.
Analyst Ratings
Cantor Fitzgerald launched coverage on Jaguar Health Inc. (NASDAQ: JAGX) in its analyst report released on July 07, 2021. The firm assigned the stock an Overweight rating. The consensus rating for Jaguar Health Inc. (JAGX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JAGX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is JAGX’s price target for the next 12 months?
Analysts predict a range of price targets between $6.00 and $6.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Jaguar Health Inc. (JAGX) stock is $6.00.
